A study to investigate the effect of lepodisiran on the occurrence of major adverse cardiovascular events (MACE) in adults with elevated Lp(a) and atherosclerotic cardiovascular disease (ASCVD) or at risk of a first CV event
Educational Partners and Supporters
(Founding Partner)
Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum.
